On the Record · Amgen

Amgen acquisitions, on the record

The businesses Amgen bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Horizon Therapeutics plc Word for word“In October 2023, we completed our acquisition of Horizon for $116.50 per share in cash, representing a total transaction price of $27.8 billion.” 10-K for 2023	acquisition	In October 2023	$116.50 per share in cash, representing a total transaction price of $27.8 billion
Bergamo subsidiary Word for word“(2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.” 10-K for 2023	divestiture	second quarter of 2023	—
Gensenta subsidiary Word for word“(2) Consists of product sales of our non-principal products, as well as sales prior to the divestiture of our Bergamo and Gensenta subsidiaries in the second quarter of 2023 and fourth quarter of 2022, respectively.” 10-K for 2023	divestiture	fourth quarter of 2022	—
ChemoCentryx Word for word“Cash used in investing activities during 2022 was primarily due to our $3.8 billion purchase of ChemoCentryx and net cash outflows related to marketable securities of $1.4 billion.” 10-K for 2023	acquisition	—	$3.8 billion purchase of ChemoCentryx
Teneobio and Five Prime Word for word“Cash provided by investing activities during 2021 was primarily due to net cash inflows related to marketable securities of $4.3 billion, partially offset by cash used in the acquisitions of Teneobio and Five Prime of $2.5 billion.” 10-K for 2023	acquisition	2021	$2.5 billion
Otezla (acquired from Bristol Myers Squibb Company) Word for word“Otezla was acquired from Bristol Myers Squibb Company in November 2019 after their acquisition of Celgene.” 10-K for 2023	acquisition	November 2019	—
Otezla (from Bristol-Myers Squibb Company) Word for word“Otezla was acquired from Bristol-Myers Squibb Company in November 2019 after its acquisition of Celgene Corporation.” 10-K for 2024	acquisition	November 2019	—
BeiGene, Ltd. Word for word“In January 2020, we acquired an equity stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China.” 10-K for 2024	acquisition	January 2020	approximately $2.8 billion in cash
Gensenta Word for word“Other operating expenses for 2022 primarily consisted of a loss on the divestiture of Gensenta.” 10-K for 2024	divestiture	—	—
Horizon Word for word“(1) TEPEZZA and KRYSTEXXA were acquired from our Horizon acquisition on October 6, 2023, and include product sales in the periods after the acquisition date.” 10-K for 2025	acquisition	October 6, 2023	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Goodwill from acquisitions
2016-12-31	$0	$0
2017-12-31	$19 million	$0
2018-12-31	−$195 million	$6 million
2019-12-31	$13.62 billion	$26 million
2020-12-31	$0	$0
2021-12-31	$2.53 billion	$251 million
2022-12-31	$3.84 billion	$651 million
2023-12-31	$26.99 billion	—
2024-12-31	$0	—
2025-12-31	$53 million	—

Deal filings since 2016

2026-02-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-10-06 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2023-03-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-03-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-02-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-12-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-08-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-02-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-08-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-07-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-04-16 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2021-03-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-05-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-12-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-11-21 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2019-10-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-10-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-08-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-11-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-05-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-01-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-08-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-06-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Amgen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.